Price
CHART BY
Frequently asked questions
What is Entrada's market capitalization?
What is the Earnings Per Share (EPS) for Entrada?
What are the analyst ratings and target price for Entrada's stock?
What is Entrada's revenue over the trailing twelve months?
What is the EBITDA for Entrada?
What is the free cash flow of Entrada?
How many employees does Entrada have, and what sector and industry does it belong to?
What is the free float of Entrada's shares?
Financials
- Market Cap
- €199.38M
- EPS (TTM)
- -€1.536
- Free Float
- 22.43M
- Revenue (TTM)
- €68.41M
- EBITDA (TTM)
- -€77.74M
- Free Cashflow (TTM)
- -€108.93M
Pricing
- 52W span
- €4.228€20.62
Analyst Ratings
The price target is €15.92 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.
- Employees
- 183
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TRDA